Effect of Inhaled Nitric Oxide on Gas Exchange in Patients with Congestive Heart Failure

1999 ◽  
Vol 130 (1) ◽  
pp. 40 ◽  
Author(s):  
Akihiro Matsumoto
Keyword(s):  
Nitric Oxide ◽  
Heart Failure ◽  
Congestive Heart Failure ◽  
Gas Exchange ◽  
Inhaled Nitric Oxide

Inhaled nitric oxide and exercise capacity in congestive heart failure

The Lancet ◽  
1997 ◽  
Vol 349 (9057) ◽  
pp. 999-1000 ◽  
Author(s):  
Akihiro Matsumoto ◽  
Shin-ichi Momomura ◽  
Yasunobu Hirata ◽  
Teruhiko Aoyagi ◽  
Seiryo Sugiura ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Heart Failure ◽  
Congestive Heart Failure ◽  
Exercise Capacity ◽  
Inhaled Nitric Oxide

scholarly journals P-389 Inhaled Nitric Oxide Increases Exercise Capacity in Patients With Congestive Heart Failure

1997 ◽  
Vol 75 ◽  
pp. 120
Author(s):  
Akihiro Matsumoto ◽  
Shin-ichi Momomura ◽  
Yasunobu Hirata ◽  
Seiryo Sugiura ◽  
Masataka Sata ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Heart Failure ◽  
Congestive Heart Failure ◽  
Exercise Capacity ◽  
Inhaled Nitric Oxide

Potential deleterious effects of inhaled nitric oxide in heart failure

1998 ◽  
Vol 4 (3) ◽  
pp. 69
Author(s):  
Shunsuke Natori ◽  
Naoyuki Hasebe ◽  
Yin-Tie Jin ◽  
Tomoyuki Matsusaka ◽  
Hideki Nakamura ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Heart Failure ◽  
Inhaled Nitric Oxide

scholarly journals Regulation of DDAH1 as a Potential Therapeutic Target for Treating Cardiovascular Diseases

2013 ◽  
Vol 2013 ◽  
pp. 1-6 ◽  
Author(s):  
Xiaoyu Liu ◽  
John Fassett ◽  
Yidong Wei ◽  
Yingjie Chen
Keyword(s):  
Nitric Oxide ◽  
Heart Failure ◽  
Congestive Heart Failure ◽  
Cardiovascular Diseases ◽  
Therapeutic Target ◽  
Farnesoid X Receptor ◽  
Nitric Oxide Synthase Inhibitor ◽  
Endogenous Nitric Oxide ◽  
Synthase Inhibitor ◽  
Nitric Oxide Bioavailability

Asymmetric dimethylarginine (ADMA) is an endogenous nitric oxide synthase inhibitor that blocks nitric oxide production, while congestive heart failure is associated with increased plasma and tissue ADMA content. Increased plasma ADMA is a strong and independent predictor of all-cause mortality in the community and the strongest predictor of mortality in patients after myocardial infarction. Recent studies demonstrated that dimethylarginine dimethylaminohydrolase-1 (DDAH1) is the critical enzyme for ADMA degradation and thereby plays an important role in maintaining cardiovascular nitric oxide bioavailability. Interestingly, activation of the farnesoid X receptor (FXR) through the bile acid ursodeoxycholic acid (UDCA) or synthetic FXR agonists, such as GW4064, can increase DDAH1 expression. Thus, modulating DDAH1 activity through FXR receptor agonists such as UDCA could be a therapeutic target for treating reduced nitric oxide bioavailability in congestive heart failure and other cardiovascular diseases.

Sign in / Sign up

Export Citation Format

Share Document